Safety, immunogenicity, and protective efficacy of the intranasal live pertussis vaccine GamLPV in an infant monkey model (<i>Papio hamadryas</i>)

INTRODUCTION. The current progressive increase in pertussis incidence and infant mortality rates is due to the insufficient effectiveness of existing vaccines, both in Russia and worldwide. Previous clinical trials showed that healthy adult volunteers developed long-term antibacterial immunity after...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	D. T. Kubrava, A. Yu. Medkova, A. Z. Matua, I. G. Kondzariya, A. A. Amichba, Kh. Z. Trapsh, L. V. Gamgiya, S. G. Kulikov, L. N. Sinyashina, Z. Ya. Mikvabiya, G. I. Karataev
Hōputu:	Artigo
Reo:	Russo
I whakaputaina:	Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2024-12-01
Rangatū:	Биопрепараты: Профилактика, диагностика, лечение
Ngā marau:	pertussis live pertussis vaccine intranasal administration monkeys hamadryas baboons papio hamadryas experimental model immunogenicity safety protective efficacy
Urunga tuihono:	https://www.biopreparations.ru/jour/article/view/596
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!